Altered microRNA expression in B lymphocytes in multiple sclerosis. Towards a better understanding of treatment effects.

Clinical Immunology

Volumn 144, Issue 1, 2012, Pages 70-79

  Sievers, Claudia ^a   Meira, Maria ^a   Hoffmann, Francine ^a   Fontoura, Paulo ^b   Kappos, Ludwig ^a   Lindberg, Raija L P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

B lymphocytes; Expression; MicroRNA; Multiple sclerosis; Natalizumab

Indexed keywords

B LYMPHOCYTE RECEPTOR; BIM PROTEIN; MESSENGER RNA; MICRORNA; NATALIZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; VIRUS RNA;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; FEMALE; HUMANS; MALE; MICRORNAS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84861674736     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.04.002     Document Type: Article

References (56)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. Bennett J.L., Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol. 2009, 32:121-132.
3. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
4. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
5. Fraussen J., Vrolix K., Martinez-Martinez P., Losen M., De Baets M.H., Stinissen P., Somers V. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun. Rev. 2009, 8:654-658.
6. Owens G.P., Bennett J.L., Gilden D.H., Burgoon M.P. The B cell response in multiple sclerosis. Neurol. Res. 2006, 28:236-244.
7. Pescovitz M.D. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 2006, 6:859-866.
8. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
9. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
10. Kappos L., Li D., Calabresi P.A., O'Connor P., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., Hauser S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
11. Hartung H.P., Kieseier B.C. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 2010, 3:205-216.
12. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007, 178:6092-6099.
13. Rose D.M., Han J., Ginsberg M.H. Alpha4 integrins and the immune response. Immunol. Rev. 2002, 186:118-124.
14. Havrdova E., Galetta S., Hutchinson M., Stefoski D., Bates D., Polman C.H., O'Connor P.W., Giovannoni G., Phillips J.T., Lublin F.D., Pace A., Kim R., Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8:254-260.
15. Lindberg R.L.P., Achtnichts L., Hoffmann F., Kuhle J., Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol. 2008, 194:153-164.
16. Krumbholz M., Meinl I., Kumpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008, 71:1350-1354.
17. Putzki N., Baranwal M.K., Tettenborn B., Limmroth V., Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur. Neurol. 2010, 63:311-317.
18. Bonig H., Wundes A., Chang K.-H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008, 111:3439-3441.
19. Lee-Chang C., Zephir H., Top I., Dubucquoi S., Trauet J., Prin L., Vermersch P. B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. Neurosci. Lett. 2011, 487:273-277.
20. Anglicheau D., Muthukumar T., Suthanthiran M. MicroRNAs: small RNAs with big effects. Transplantation 2010, 90:105-112.
21. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun. Rev. 2009, 8:520-524.
22. Taganov K.D., Boldin M.P., Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 2007, 26:133.
23. Rodriguez A., Vigorito E., Clare S., Warren M.V., Couttet P., Soond D.R., van Dongen S., Grocock R.J., Das P.P., Miska E.A., Vetrie D., Okkenhaug K., Enright A.J., Dougan G., Turner M., Bradley A. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
24. Gantier M.P., Sadler A.J., Williams B.R.G. Fine-tuning of the innate immune response by microRNAs. Immunol. Cell Biol. 2007, 85:458-462.
25. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136:26-36.
26. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
27. Kotani A., Harnprasopwat R., Toyoshima T., Kawamata T., Tojo A. miRNAs in normal and malignant B cells. Int. J. Hematol. 2010, 92:255-261.
28. Liang T.J., Qin C.Y. The emerging role of microRNAs in immune cell development and differentiation. APMIS 2009, 117:635-643.
29. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., Henderson J.M., Kutok J.L., Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008, 9:405-414.
30. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., Newman J., Bronson R.T., Crowley D., Stone J.R., Jaenisch R., Sharp P.A., Jacks T. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
31. Lindberg R.L.P., Hoffmann F., Mehling M., Kuhle J., Kappos L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 2010, 40:888-898.
32. Xiao C., Calado D.P., Galler G., Thai T.H., Patterson H.C., Wang J., Rajewsky N., Bender T.P., Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
33. Zhou B., Wang S., Mayr C., Bartel D.P., Lodish H.F. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7080-7085.
34. Otaegui D., Baranzini S.E., Armananzas R., Calvo B., Munoz-Culla M., Khankhanian P., Inza I., Lozano J.A., Castillo-Trivino T., Asensio A., Olaskoaga J., de Munain A.L. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009, 4:e6309.
35. Keller A., Leidinger P., Lange J., Borries A., Schroers H., Scheffler M., Lenhof H.-P., Ruprecht K., Meese E. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009, 4:e7440.
36. Du C., Liu C., Kang J., Zhao G., Ye Z., Huang S., Li Z., Wu Z., Pei G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10:1252-1259.
37. De Santis G., Ferracin M., Biondani A., Caniatti L., Rosaria Tola M., Castellazzi M., Zagatti B., Battistini L., Borsellino G., Fainardi E., Gavioli R., Negrini M., Furlan R., Granieri E. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J. Neuroimmunol. 2010, 226:165-171.
38. Tanzer A., Stadler P.F. Molecular evolution of a microRNA cluster. J. Mol. Biol. 2004, 339:327-335.
39. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., Newman J., Bronson R.T., Crowley D., Stone J.R., Jaenisch R., Sharp P.A., Jacks T. Targeted deletion reveals essential and overlapping functions of the miR-17 92 family of miRNA clusters. Cell 2008, 132:875-886.
40. Jima D.D., Zhang J., Jacobs C., Richards K.L., Dunphy C.H., Choi W.W.L., Yan Au W., Srivastava G., Czader M.B., Rizzieri D.A., Lagoo A.S., Lugar P.L., Mann K.P., Flowers C.R., Bernal-Mizrachi L., Naresh K.N., Evens A.M., Gordon L.I., Luftig M., Friedman D.R., Weinberg J.B., Thompson M.A., Gill J.I., Liu Q., How T., Grubor V., Gao Y., Patel A., Wu H., Zhu J., Blobe G.C., Lipsky P.E., Chadburn A., Dave S.S. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010, 116:e118-e127. C. for the Hematologic Malignancies Research.
41. Suzuki A., Kaisho T., Ohishi M., Tsukio-Yamaguchi M., Tsubata T., Koni P.A., Sasaki T., Mak T.W., Nakano T. Critical roles of PTEN in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 2003, 197:657-667.
42. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
43. Baracho G.V., Miletic A.V., Omori S.A., Cato M.H., Rickert R.C. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr. Opin. Immunol. 2011, 23:178-183.
44. Marshall A.J., Niiro H., Yun T.J., Clark E.A. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol. Rev. 2000, 176:30-46.
45. Lindsay M.A. MicroRNAs and the immune response. Trends Immunol. 2008, 29:343-351.
46. Schwab N., Schneider-Hohendorf T., Posevitz V., Breuer J., Göbel K., Kleinschnitz C., Kieseier B.C., Wiendl H. Effects of Natalizumab treatment on immune cell populations and T-cell function-possible implications for PML risk stratification. Mult. Scler. J. 2011, 17:S512.
47. Noren Hooten N., Abdelmohsen K., Gorospe M., Ejiogu N., Zonderman A.B., Evans M.K. microRNA expression patterns reveal differential expression of target genes with age. PLoS ONE 2010, 5:e10724.
48. Lucas R.M., Ponsonby A.L., Dear K., Valery P., Pender M.P., Burrows J.M., Burrows S.R., Chapman C., Coulthard A., Dwyer D.E., Dwyer T., Kilpatrick T., Lay M.L.J., McMichael A.J., Taylor B.V., van der Mei I.A.F., Williams D. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011, 77:371-379.
49. Barth S., Meister G., Grässer F.A. EBV-encoded miRNAs. Biochim. Biophys. Acta 2011, 1809:631-640.
50. Marquitz A.R., Mathur A., Nam C.S., Raab-Traub N. The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 2011, 412:392-400.
51. Choy E.Y.-W., Siu K.-L., Kok K.-H., Lung R.W.-M., Tsang C.M., To K.-F., Kwong D.L.-W., Tsao S.W., Jin D.-Y. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 2008, 205:2551-2560.
52. Dölken L., Malterer G., Erhard F., Kothe S., Friedel C.C., Suffert G., Marcinowski L., Motsch N., Barth S., Beitzinger M., Lieber D., Bailer S.M., Hoffmann R., Ruzsics Z., Kremmer E., Pfeffer S.b., Zimmer R., Koszinowski U.H., Grässer F., Meister G., Haas J.r. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human γ-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 2010, 7:324-334.
53. Yang I.V., Wade C.M., Kang H.M., Alper S., Rutledge H., Lackford B., Eskin E., Daly M.J., Schwartz D.A. Identification of novel genes that mediate innate immunity using inbred mice. Genetics 2009, 183:1535-1544.
54. Stern-Ginossar N., Elefant N., Zimmermann A., Wolf D.G., Saleh N., Biton M., Horwitz E., Prokocimer Z., Prichard M., Hahn G., Goldman-Wohl D., Greenfield C., Yagel S., Hengel H., Altuvia Y., Margalit H., Mandelboim O. Host immune system gene targeting by a viral miRNA. Science 2007, 317:376-381.
55. Bauman Y., Nachmani D., Vitenshtein A., Tsukerman P., Drayman N., Stern-Ginossar N., Lankry D., Gruda R., Mandelboim O. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 2011, 9:93-102.
56. Seo G.J., Fink L.H.L., O'Hara B., Atwood W.J., Sullivan C.S. Evolutionarily conserved function of a viral microRNA. J. Virol. 2008, 82:9823-9828.